口蹄疫病毒病毒样颗粒研究进展

摘要/Abstract

摘要： 口蹄疫病毒病毒样颗粒(virus-like particles,VLPs)是不含口蹄疫病毒RNA的空衣壳结构,由口蹄疫病毒的4种结构蛋白体外自组装形成的,形态上与天然病毒粒子相似,具有很强的免疫原性和生物学活性。文章介绍了口蹄疫病毒衣壳的组装、口蹄疫病毒VLPs在国内外的研究进展和影响VLPs形成的因素,并对VLPs在疫苗研制等方面的应用前景作了展望。

关键词: 口蹄疫病毒; 病毒样颗粒; 组装; 疫苗

Abstract: Foot-and-mouth disease virus (FMDV) virus-like particles (VLPs) are particles lack virus-specific genetic materials (RNA), which are self-assembled by four structural proteins and are similar to natural virus particles in morphology. Also, VLPs have better biological activity and immunogenicity. This review focuses on the assembly of FMDV capsid, advances on VLPs, the influencing factors of forming VLPs, and the prospect of the development and application of FMDV VLPs vaccines.

Key words: foot-and-mouth disease virus; virus-like particles (VLPs); assembly; vaccines

中图分类号:

S852.65

张庆勋, 刘新生, 周鹏, 方玉珍, 王永录, 张永光. 口蹄疫病毒病毒样颗粒研究进展[J]. , 2014, 41(11): 258-262.

ZHANG Qing-xun, LIU Xin-sheng, ZHOU Peng, FANG Yu-zhen, WANG Yong-lu, ZHANG Yong-guang. Research Progress on Foot-and-mouth Disease Virus Virus-like Particles[J]. , 2014, 41(11): 258-262.

参考文献

1 宋妮,温永俊,王凤,等. 利用SUMO表达系统高效表达猪O型口蹄疫病毒VP0、VP1、VP3基因[J]. 中国畜牧兽医,2013,40(9):61～65.
2 Abrams C C, King A M Q, Belsham G J. Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system[J]. Journal of General Virology, 1995, 76(12): 3089～3098.
3 Belsham G J. Distinctive features of foot-and-mouth disease virus, a member of the picornavirus family; aspects of virus protein synthesis, protein processing and structure[J]. Prog Biophys Mol Biol, 1993, 60(3): 241～260.
4 Berger I, Fitzgerald D J, Richmond T J. Baculovirus expression system for heterologous multiprotein complexes[J]. Nature Biotechnology, 2004, 22(12): 1583～1587.
5 Bhat S A, Saravanan P, Hosamani M, et al. Novel immunogenic baculovirus expressed virus-like particles of foot-and-mouth disease (FMD) virus protect guinea pigs against challenge[J]. Research in Veterinary Science, 2013, 95(3): 1217～1223.
6 Cao Y, Lu Z, Sun J, et al. Synthesis of empty capsid-like particles of AsiaⅠfoot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs[J]. Veterinary Microbiology, 2009, 137(1): 10～17.
7 Cao Y, Sun P, Fu Y, et al. Formation of virus-like particles from O-type foot-and-mouth disease virus in insect cells using codon-optimized synthetic genes[J]. Biotechnology Letters, 2010, 32(9): 1223～1229.
8 Catanzariti A M, Soboleva T A, Jans D A, et al. An efficient system for high-level expression and easy purification of authentic recombinant proteins[J]. Protein Science, 2004, 13(5): 1331～1339.
9 Clarke B E, Newton S E, Carroll A R, et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein[J]. Nature, 1987, 330(6146): 381～384.
10 Curry S, Abrams C C, Fry E, et al. Viral RNA modulates the acid sensitivity of foot-and-mouth disease virus capsids[J]. Journal of Virology, 1995, 69(1): 430～438.
11 Dong H, Guo H C, Sun S Q. Virus-like particles in picornavirus vaccine development[J]. Applied Microbiology and Biotechnology, 2014, 98(10): 4321～4329.
12 Freivalds J, Dislers A, Ose V, et al. Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastoris[J]. Protein Expression and Purification, 2011, 75(2): 218～224.
13 Goodwin S, Tuthill T J, Arias A, et al. Foot-and-mouth disease virus assembly: Processing of recombinant capsid precursor by exogenous protease induces self-assembly of pentamers in vitro in a myristoylation-dependent manner[J]. Journal of Virology, 2009, 83(21): 11275～11282.
14 Grgacic E V L, Anderson D A. Virus-like particles: Passport to immune recognition[J]. Methods, 2006, 40(1): 60～65.
15 Grillberger L, Kreil T R, Nasr S, et al. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells[J]. Biotechnology Journal, 2009, 4(2): 186～201.
16 Grote A, Hiller K, Scheer M, et al. JCat: A novel tool to adapt codon usage of a target gene to its potential expression host[J]. Nucleic Acids Research, 2005, 33(suppl 2): W526～W531.
17 Grubman M J, Baxt B. Foot-and-mouth disease[J]. Clinical Microbiology Reviews, 2004, 17(2): 465～493.
18 Gullberg M, Polacek C, Bøtner A, et al. Processing of the VP1/2A junction is not necessary for production of foot-and-mouth disease virus empty capsids and infectious viruses: Characterization of "self-tagged" particles[J]. Journal of Virology, 2013, 87(21): 11591～11603.
19 Guo H C, Sun S Q, Jin Y, et al. Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle[J]. Veterinary Research, 2013, 44(1): 48～60.
20 Jewell J E, Ball L A, Rueckert R. Limited expression of poliovirus by vaccinia virus recombinants due to inhibition of the vector by proteinase 2A[J]. Journal of Virology, 1990, 64(3): 1388～1393.
21 Kushnir N, Streatfield S J, Yusibov V. Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development[J]. Vaccine, 2012, 31(1): 58～83.
22 Lee C D, Sun H C, Hu S M, et al. An improved SUMO fusion protein system for effective production of native proteins[J]. Protein Science, 2008, 17(7): 1241～1248.
23 Lee C D, Yan Y P, Liang S M, et al. Production of FMDV virus-like particles by a SUMO fusion protein approach in Escherichia coli[J]. Journal of Biomedical Science, 2009, 16(1): 69～75.
24 Li Z, Yi Y, Yin X, et al. Expression of foot-and-mouth disease virus capsid proteins in silkworm-baculovirus expression system and its utilization as a subunit vaccine[J]. PLoS One, 2008, 3(5): e2273.
25 Mackett M, Smith G L. Vaccinia virus expression vectors[J]. Journal of General Virology, 1986, 67(10): 2067～2082.
26 Marblestone J G, Edavettal S C, Lim Y, et al. Comparison of SUMO fusion technology with traditional gene fusion systems: Enhanced expression and solubility with SUMO[J]. Protein Science, 2006, 15(1): 182～189.
27 Mohana Subramanian B, Madhanmohan M, Sriraman R, et al. Development of foot-and-mouth disease virus (FMDV) serotype O virus-like-particles (VLPs) vaccine and evaluation of its potency[J]. Antiviral Research, 2012, 96(3): 288～295.
28 Pan L, Zhang Y, Wang Y, et al. Foliar extracts from transgenic tomato plants expressing the structural polyprotein, P1-2A, and protease, 3C, from foot-and-mouth disease virus elicit a protective response in guinea pigs[J]. Veterinary Immunology and Immunopathology, 2008, 121(1): 83～90.
29 Paprocka G. Foot-and-mouth disease vaccines[J]. Medycyna Weterynaryjna, 2013, 69(11): 643～648.
30 Porta C, Xu X, Loureiro S, et al. Efficient production of foot-and-mouth disease virus empty capsids in insect cells following down regulation of 3C protease activity[J]. Journal of Virological Methods, 2013, 187(2): 406～412.
31 Rodriguez L L, Gay C G. Development of vaccines toward the global control and eradication of foot-and-mouth disease[J]. Expert Review of Vaccines, 2011, 10(3): 377～387.
32 Roldâo A, Mellado M C M, Castilho L R, et al. Virus-like particles in vaccine development[J]. Expert Review of Vaccines, 2010, 9(10): 1149～1176.
33 Roosien J, Belsham G J, Ryan M D, et al. Synthesis of foot-and-mouth disease virus capsid proteins in insect cells using baculovirus expression vectors[J]. Journal of General Virology, 1990, 71(8): 1703～1711.
34 Ryan M D, Drew J. Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein[J]. The EMBO Journal, 1994, 13(4): 928～933.
35 Sorensen M A, Kurland C G, Pedersen S. Codon usage determines translation rate in Escherichia coli[J]. Journal of Molecular Biology, 1989, 207(2): 365～377.
36 Sun X H, Baltimore D. Human immunodeficiency virus tat-activated expression of poliovirus protein 2A inhibits mRNA translation[J]. Proceedings of the National Academy of Sciences, 1989, 86(7): 2143～2146.
37 Yusibov V, Rabindran S. Recent progress in the development of plant derived vaccines[J]. Expert Rev Vaccines, 2008, 7(8): 1173～1183.
38 Zhang W, Carmichael J, Ferguson J, et al. Expression of human papillomavirus type 16 L1 protein in Escherichia coli: Denaturation, renaturation, and self-assembly of virus-like particles in vitro[J]. Virology, 1998, 243(2): 423～431.
39 zur Megede J, Chen M C, Doe B, et al. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene[J]. Journal of Virology, 2000, 74(6): 2628～2635.

[1]	韩冰, 汤思淇, 朱大帷, 李海玲, 冯亚莉, 苏超凡, 徐艺娜, 冷昊钰, 王永涛, 张月美, 太晓春, 张莹. 新型疫苗佐剂研究进展[J]. 中国畜牧兽医, 2023, 50(6): 2460-2467.
[2]	余新刚, 袁凯健, 穆宣儒, 王红彩, 戚南山, 张浩吉. 贾第虫包囊壁形成及囊壁蛋白研究进展[J]. 中国畜牧兽医, 2023, 50(5): 2061-2068.
[3]	陈天宝, 王娅妮, 刘宝玲, 王刚, 王晓虎, 柳旭辉, 蔡汝健, 贺东生. 中药抗猪繁殖与呼吸综合征病毒的作用机制研究进展[J]. 中国畜牧兽医, 2023, 50(5): 2114-2129.
[4]	陈吉敏, 李辉煌, 赖连杰, 杨银华, 杨悦, 林瑞意. 鸭坦布苏病毒检测方法及疫苗研究进展[J]. 中国畜牧兽医, 2023, 50(4): 1329-1339.
[5]	刘新月, 栗利芳, 王振豹, 张文亮, 张欣, 赵洪涛, 李鹏宇, 郑昊天, 肖进, 齐鹏. 猪圆环病毒2型合成肽疫苗佐剂筛选与免疫保护性研究[J]. 中国畜牧兽医, 2023, 50(3): 1068-1080.
[6]	刘馨, 潘吉脉, 胡安东, 曾成容, 杨颖, 程振涛, 陈江凤, 姜海波, 文明. 黄芪多糖对杂交鲟用嗜水气单胞菌灭活疫苗的影响[J]. 中国畜牧兽医, 2023, 50(3): 1177-1184.
[7]	李琦, 田野, 黄涛, 刘存霞. 纳米疫苗在禽流感防控中的研究进展[J]. 中国畜牧兽医, 2023, 50(2): 684-692.
[8]	徐景峨, 李婷, 陈汝佳, 余波, 张亚楠, 杨莉, 赵滨, 蒲龄. 鸭疫里氏杆菌二价灭活疫苗制备及免疫效力研究[J]. 中国畜牧兽医, 2023, 50(1): 290-299.
[9]	刘宏莹, 王婧瑜, 崔珍珍, 马青霞, 汪婷婷, 李健明, 时坤, 宫庆龙, 杜锐, 冷雪. 中药有效成分对动物疫苗的免疫佐剂效果及相关机理研究进展[J]. 中国畜牧兽医, 2023, 50(1): 390-397.
[10]	赵逢淼, 郭婷, 周雅坪, 赵红梅, 王宇琛, 田广原, 孙雅婕, 卞宇晨, 于佳梁, 郝永清. 牛病毒性腹泻病毒对新西兰白兔致病性分析及E2蛋白免疫效果的评价[J]. 中国畜牧兽医, 2022, 49(9): 3549-3558.
[11]	贾新月, 马静, 张艳艳, 马勋, 王正荣, 薄新文. 动物寄生虫口服疫苗研究进展[J]. 中国畜牧兽医, 2022, 49(9): 3569-3580.
[12]	徐娅玲, 张霁辉, 牛熙, 李升, 黄世会, 冉雪琴, 王嘉福. 非洲猪瘟病毒P72蛋白合成肽疫苗的构建及其免疫效力评估[J]. 中国畜牧兽医, 2022, 49(8): 3083-3090.
[13]	王宇琛, 田广原, 周雅坪, 郭婷, 赵红梅, 孙雅婕, 赵逢淼, 卞宇晨, 于佳梁, 郝永清. BPIV3 NP蛋白的原核表达及其对BPIV3灭活疫苗免疫增强作用的研究[J]. 中国畜牧兽医, 2022, 49(8): 3122-3130.
[14]	马光强, 刘丽娟, 陈国权, 吴良涛, 杨均, 刘军泽, 李潇蒙, 潘成文, 周碧君. 鸭疫里默氏杆菌贵州流行株蜂胶灭活疫苗制备[J]. 中国畜牧兽医, 2022, 49(8): 3163-3170.
[15]	田宇杰, 李婷, 代国滔, 蒲龄, 张亚楠, 袁超, 杨茂生, 陈强, 李美娟, 徐景峨. A:L1型鸭源多杀性巴氏杆菌灭活疫苗制备及免疫效力研究[J]. 中国畜牧兽医, 2022, 49(7): 2716-2724.